Company intelligence / Profile preview

CyanVac LLC

Athens, Georgia, United Statescyanvacllc.com ↗

Ownership: Private
Development stage: Phase 2

Overview

CyanVac's lead COVID-19 vaccine candidate CVXGA has completed Phase 1 studies in adults and teens and a Phase 2 placebo-controlled study in younger and older adults. The RSV vaccine candidate BLB-201 is in Phase 1 clinical trials and has received Fast Track designation from the FDA. The company has demonstrated that subjects dosed with CVXGA showed robust mucosal, cellular and humoral immune responses with limited or no reactogenicity and no serious events assessed as related to the vaccine.

Therapeutic areas: Infectious Diseases
Modalities: Intranasal vaccinesPIV5-based vector vaccines
Industry: Biotech

Drug pipeline

7 assets

CVXGA

6 more assets in the full pipeline.

Request access →

Partnerships

Immuno Technologies, Inc.

Beyond the preview

Go deeper on CyanVac LLC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CyanVac LLC.

Explore the full profile